Compare VRME & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | IMNN |
|---|---|---|
| Founded | 1999 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 12.9M |
| IPO Year | N/A | 1985 |
| Metric | VRME | IMNN |
|---|---|---|
| Price | $0.68 | $3.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.50 | ★ $182.61 |
| AVG Volume (30 Days) | ★ 445.9K | 33.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $3.56 |
| 52 Week High | $5.00 | $41.22 |
| Indicator | VRME | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 39.01 |
| Support Level | $0.63 | $3.80 |
| Resistance Level | $0.72 | $4.00 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 14.90 | 0.00 |
VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).